Prior studies describe ARRDC3 as a tumor suppressor in other cancers, where it attenuates GPCR signaling and limits invasion, and additional evidence links ARRDC3 polymorphisms and expression to glioma susceptibility and adverse outcomes in related malignancies (39, 40). Here, ARRDC3 is linked to glioma.